| INvestigation of TENS Efficacy Versus Posterior Tibial Nerve Stimulation for Overactive Bladder (NCT05309993) | University of New Mexico | 2022-06-30 |
| Study of V117957 in Overactive Bladder Syndrome (NCT06024642) | Imbrium Therapeutics | 2022-06-30 |
| Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial (NCT05308979) | University of California, Irvine | 2022-05-01 |
| Virtual Bladder Training for Overactive Bladder Syndrome in Women. Which Symptom Responds Better? (NCT05493748) | Hospital Italiano de Buenos Aires | 2022-05-01 |
| Darifenacin x Parasacral Transcutaneous Electric Nerve Stimulation for OAB in Patients Infected With Human T-Lymphotropic Virus 1 (NCT06616675) | Hospital Universitário Professor Edgard Santos | 2022-03-16 |
| Comparing Number of Injection Sites of In-office Intravesical Onabotulinumtoxin A Treatments for Overactive Bladder: A Randomized Controlled Trial (NCT05157295) | Augusta University | 2022-01-01 |
| BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder (NCT04873037) | Corewell Health East | 2021-11-22 |
| Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial (NCT05188742) | Taipei Veterans General Hospital, Taiwan | 2021-11-10 |
| Oxybutynin for Post-surgical Bladder Pain and Urgency (NCT03952299) | University of California, Davis | 2021-09-01 |
| Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome (NCT05040984) | Far Eastern Memorial Hospital | 2021-04-30 |
| Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder (NCT04909255) | China Medical University Hospital | 2021-03-23 |
| Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker (NCT04693897) | Chang Gung Memorial Hospital | 2021-03-01 |
| Comparison and Evaluation of USSQ, OABSS, and the Drainage/Anti-reflux Effect Between Three Kinds of Ureteral D-J Stents in Patients Who Underwent URL (NCT04858750) | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 2021-02-01 |
| BE Technologies Mobile Uroflowmetry Validation Study (NCT04599283) | BE Technologies Inc | 2020-08-18 |
| Minimizing Pain During Office Intradetrussor Botox Injection (NCT04270526) | Boston Urogynecology Associates | 2020-08-15 |
| Tolterodine Relieves Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome (NCT05250245) | Yuzuncu Yil University | 2020-06-01 |
| Overactive Bladder Syndrome (NCT05151081) | Hisar Intercontinental Hospital | 2020-02-03 |
| Comparison of Different Treatments for Overactive Bladder Syndrome (NCT04197466) | Ankara Yildirim Beyazıt University | 2019-12-06 |
| Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder (NCT06123364) | Serdinsek Tamara | 2019-10-14 |
| Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin (NCT04023253) | Far Eastern Memorial Hospital | 2019-08-01 |
| Efficacy of Transcutaneous Versus Percutaneous Posterior Tibial Nerve Stimulation in the Overactive Bladder. (NCT04483817) | Fisiocore LC,SL | 2019-07-17 |
| Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome (NCT03695822) | Far Eastern Memorial Hospital | 2018-12-24 |
| Effects of Kinesio Taping Application in Women With Overactive Bladder (NCT03817203) | Ataturk Training and Research Hospital | 2018-11-15 |
| TTNS Versus Sham Therapy for Children With iOAB (TaPaS Part I) (NCT04256876) | University Hospital, Ghent | 2018-11-07 |
| Oral vs Intravesical Analgesia for Office Bladder Botox Injections (NCT03755089) | Women and Infants Hospital of Rhode Island | 2018-11-01 |
| Treatment of the Overactive Bladder Syndrome: A Delphi Study (NCT04300400) | University Hospital, Ghent | 2018-10-16 |
| Use of Repris Needle in Bladder Injection (NCT04982120) | Uro-1 Medical | 2018-10-15 |
| Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin (NCT03758235) | University Of Perugia | 2018-09-01 |
| OnabotulinumtoxinA Bladder Injection Study (NCT03523091) | Corewell Health East | 2018-08-08 |
| Experience Sampling Method in OAB Patients (NCT03435991) | Maastricht University Medical Center | 2018-08-06 |
| Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP (NCT03632772) | Buddhist Tzu Chi General Hospital | 2018-08-01 |
| Effect of Ureteral Stents Length and Location on Related Symptom (NCT05069376) | Taipei Medical University Shuang Ho Hospital | 2018-06-12 |
| Condensed Percutaneous Tibial Nerve Stimulation (PTNS) Protocol (NCT03559946) | Stony Brook University | 2018-06-08 |
| Herbal Patch for Overactive Bladder (NCT03532789) | En Chu Kong Hospital | 2018-05-14 |
| Effectiveness of Bilateral PTNS Compared to Unilateral PTNS for the Treatment of Overactive Bladder/Urge Incontinence (NCT03535857) | Gnankang Sarah Napoe | 2018-04-17 |
| Efficacy of Different Electrical Stimulation Placement in Patients With Overactive Bladder Syndrome (NCT03516435) | Chung Shan Medical University | 2018-04-09 |
| OptiLUTS Part C: the Development of a Symptom Assessment Tool in Sacral Neuromodulation. (NCT05313984) | University Hospital, Ghent | 2018-03-01 |
| Efficacy of Lower Limb Exercises on Overactive Bladder Symptoms in Patients With Multiple Sclerosis (NCT03322748) | IRCCS San Raffaele | 2018-02-01 |
| Effects of Bladder Training and Pelvic Floor Muscle Training on the Symptomatology of Overactive Bladder Syndrome (NCT03331081) | Federal University of São Paulo | 2017-11-25 |
| Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing (NCT03251300) | Far Eastern Memorial Hospital | 2017-08-01 |
| Urodynamics and Clinical Factors That Are Associated With Bladder Over-sensitivity (NCT03486639) | Assaf-Harofeh Medical Center | 2017-07-01 |
| Physiotherapy in Overactive Bladder: Electrical Stimulation Treatment (NCT03250650) | University of Sao Paulo General Hospital | 2017-03-09 |
| Central Obesity in Cases of OAB (NCT03750604) | Mansoura University | 2017-01-01 |
| Effectiveness of a Structured Intervention to Optimize the Use of Mirabegron (NCT03536494) | Catalan Institute of Health | 2017-01-01 |
| Overactive Bladder in Elderly Patients- An Early Warning of Coronary Artery Disease (NCT02854813) | Ankara Training and Research Hospital | 2016-01-01 |
| Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan (NCT03044912) | Buddhist Tzu Chi General Hospital | 2015-11-16 |
| Trigonal vs Non Trigonal Botox Injection in OAB. (NCT03533062) | Mansoura University | 2015-06-14 |
| Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan (NCT03059134) | Buddhist Tzu Chi General Hospital | 2015-04-28 |
| Correlations of 3D Urethral and Paraurethral Sonographic Findings With Urodynamic Studies, Lower Urinary Tract Symptoms & Sexual Dysfunction in Female Patients With Lower Urinary Tract Symptoms. (NCT01884753) | Far Eastern Memorial Hospital | 2014-02-02 |
| Comparison of Posterior Tibial Nerve Electrical Stimulation Protocols for Overactive Bladder Syndrome (NCT01912885) | University of Sao Paulo General Hospital | 2013-10-09 |
| Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients (NCT01876186) | National Taiwan University Hospital | 2013-05-01 |
| Antimuscarinic Treatment for Female Patients With Overactive Bladder Syndrome: Comparison of Daytime and Nighttime Dosing (NCT01819168) | Far Eastern Memorial Hospital | 2013-03-01 |
| Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug (NCT01627145) | National Taiwan University Hospital | 2012-08-01 |
| Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome (NCT02024945) | Takeda | 2010-11-01 |
| Intravesical Injection of Botox for Treating Therapy Refractory Overactive Bladder in Females (NCT01042119) | University of Zurich | 2010-01-01 |
| Basic Sensations Coming From the Bladder (NCT01114412) | Maastricht University Medical Center | 2009-09-01 |
| Overactive Bladder (OAB) Drink Advice Study (NCT00982241) | Radboud University Medical Center | 2009-07-01 |
| The Effect of Position on Urge Sensation in Volunteers and in Patients With Overactive Bladder Syndrome (NCT00821314) | Maastricht University Medical Center | 2009-04-01 |
| Trial of Maintenance Therapy With Posterior Tibial Nerve Stimulation for Overactive Bladder (NCT00912314) | University of California, San Diego | 2009-02-01 |
| Cystoscopy Plus Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding (NCT00839969) | Medway NHS Foundation Trust | 2009-01-01 |
| Colonization of the Female Urethra With Mycoplasma Hominis, Ureaplasma Urealyticum, Chlamydia Trachomatis, or Neisseria Gonorrhea in Patients With Lower Urinary Tract Symptoms (NCT01559623) | University of Zurich | 2009-01-01 |
| Effect of Pulse Rate Changes on Clinical Outcome (NCT01164280) | Maastricht University Medical Center | 2008-07-01 |
| Non-Micturation Bladder Activity in Relation to Self-Consciousness During Filling Phase and Sensation Measurement During the Filling Phase (NCT00628615) | Maastricht University Medical Center | 2008-04-01 |
| Validation of a Real-time Urodynamic Measure of Urinary Urgency (NCT00909428) | Loyola University | 2007-01-01 |
| Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity (NCT00335660) | Avera Pharmaceuticals | 2006-06-01 |
| Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome (NCT00220402) | Pfizer | 2004-07-01 |
| Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome (NCT00220376) | Pfizer | 2004-04-01 |
| A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder. (NCT00171145) | Novartis | 2004-04-01 |
| A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome (NCT00220363) | Pfizer | 2004-01-01 |
| A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder (NCT00170755) | Novartis | 2002-04-01 |